<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Meningitis in Children</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="neurology-febrile-seizures.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 84.6%;"></div>
                        </div>
                       <span class="progress-text">Lecture 11 of 13</span>
                    </div>
                    <a href="neurology-other-conditions.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">MENINGITIS IN CHILDREN</h1>
                <p class="toc-subtitle">ASHIONO E.M</p>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <!-- START: definitions -->
                <section id="definitions" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Definitions</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li><strong>Meningitis</strong> - inflammation of the meninges</li>
                            <li><strong>Encephalitis</strong> - infection of the brain parenchyma</li>
                            <li><strong>Meningoencephalitis</strong> - inflammation of brain + meninges</li>
                            <li><strong>Aseptic meningitis</strong> - inflammation of meninges with sterile CSF</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-02-1.jpg" alt="Anatomical illustration showing the layers of the meninges surrounding the brain: dura mater, arachnoid mater, and pia mater." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: definitions -->

                <!-- START: epidemiology-kenya -->
                <section id="epidemiology-kenya" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Epidemiology in Kenya</span>
                    </h2>
                    <div class="content-card">
                        <p>A study in a rural Kenyan hospital showed:</p>
                        <ul>
                            <li>390 cases (1.3% of all admissions), 88% were &lt;5 years old.</li>
                            <li>The apparent minimum annual incidence in children under 5 increased from 120 to 202 per 100,000 between 1995 and 2000.</li>
                            <li>The most common organisms in infants &lt;3 months were streptococci and Enterobacteriaceae.</li>
                            <li>Streptococcus pneumoniae (43.1%) and Haemophilus influenzae (41.9%) were predominant in the postneonatal period.</li>
                            <li>Overall mortality was 30.1%, and 23.5% of survivors developed neurologic sequelae.</li>
                            <li>Chloramphenicol resistance of H. influenzae rose from 8% in 1994 to 80% in 2000, accompanied by an apparent increase in mortality.</li>
                        </ul>
                        <h3 class="subsection-heading">Kenyatta National Hospital (KNH) Neonates Study</h3>
                        <ul>
                            <li>The prevalence of meningitis amongst cases of suspected sepsis was 17.9%.</li>
                            <li>Feed intolerance and lethargy were the most common clinical features (73.3% and 60% respectively).</li>
                            <li>The most common aetiological agents were Escherichia coli (46.7%), Group B Streptococci (26.7%), and Klebsiella pneumoniae (13.3%).</li>
                            <li>Most isolates were resistant to ampicillin and gentamicin but showed good in-vitro sensitivities to amikacin, cefuroxime, and third-generation cephalosporins.</li>
                            <li>Resistance to first-line antibiotics (penicillin and gentamicin) is high, suggesting a need to change empirical antibiotic use.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: epidemiology-kenya -->

                <!-- START: transmission-and-pathogens -->
                <section id="transmission-and-pathogens" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Transmission and Pathogens</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Transmission</h3>
                        <ul>
                            <li>Droplet transmission from person to person through close and prolonged contact (e.g., sneezing, coughing).</li>
                            <li>Incubation period is 2-10 days.</li>
                        </ul>
                        <h3 class="subsection-heading">Routes of Infection</h3>
                        <ul>
                            <li>Nasopharynx</li>
                            <li>Bloodstream</li>
                            <li>Direct spread (skull fracture, meningo/encephalocele)</li>
                            <li>Middle ear infection</li>
                            <li>Infected VP shunts</li>
                            <li>Congenital defects</li>
                            <li>Sinusitis</li>
                        </ul>
                        <h3 class="subsection-heading">Bacterial Meningitis Organisms</h3>
                        <ul>
                            <li><strong>Neonates (0-7 days):</strong> Group B Streptococci (GBS), E. coli, other enteric bacilli, L. monocytogenes.</li>
                            <li><strong>Neonates (>7 days):</strong> Same as above, plus consider antimicrobial-resistant gram-negative organisms and gram-positive organisms in hospitalized infants.</li>
                            <li><strong>Older infants and children:</strong> Neisseria meningitidis, S. pneumoniae, Tuberculosis, H. influenzae.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: transmission-and-pathogens -->

                <!-- START: pathogenesis -->
                <section id="pathogenesis" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Pathogenesis of Bacterial Meningitis</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Entry of organism through the Blood-Brain Barrier (BBB).</li>
                            <li>Release of bacterial cell wall and membrane products.</li>
                            <li>Outpouring of polymorphs and fibrin.</li>
                            <li>Release of cytokines and chemokines.</li>
                            <li>Activation of inflammatory mediators.</li>
                            <li>Inflamed meninges become covered with exudate.</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-16-1.jpg" alt="Flowchart showing the inflammatory cascade in meningococcal septicemia, from bacterial components to inflammatory mediators and resulting in coagulation, fibrinolysis, and organ failure." class="content-image">
                            <figcaption>The inflammatory cascade in meningococcal septicaemia.</figcaption>
                        </figure>
                        <h3 class="subsection-heading">Microvascular Injury in Meningococcal Sepsis</h3>
                        <p>The complex physiology of meningococcal sepsis is largely explained by four basic processes affecting the microvasculature:</p>
                        <ol>
                            <li>Increased vascular permeability</li>
                            <li>Pathological vasoconstriction and vasodilatation</li>
                            <li>Loss of thromboresistance and intravascular coagulation</li>
                            <li>Profound myocardial dysfunction.</li>
                        </ol>
                        <p>These events are largely responsible for the development of shock and multiorgan failure.</p>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-19-1.jpg" alt="Diagram showing the linked inflammatory, coagulation, and fibrinolytic pathways leading to organ failure." class="content-image">
                            <figcaption>(A) The inflammatory, coagulation, and fibrinolytic pathways are linked at many levels, leading to organ failure and eventually death.</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-19-2.jpg" alt="Diagram illustrating the mechanisms of increased vascular permeability in sepsis." class="content-image">
                            <figcaption>(B) Increased vascular permeability</figcaption>
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-20-1.jpg" alt="Diagram showing factors involved in intravascular thrombosis and purpura fulminans." class="content-image">
                            <figcaption>Factors involved in intravascular thrombosis and purpura fulminans.</figcaption>
                        </figure>
                        <h3 class="subsection-heading">Neurologic Injury</h3>
                        <ul>
                            <li>Direct bacterial toxicity</li>
                            <li>Indirect inflammatory processes such as cytokine release, neutrophil activation, with resultant vasculitis, and cellular oedema</li>
                            <li>Cerebral oedema may be caused by increased secretion of CSF, diminished reabsorption of CSF, and breakdown of the blood-brain barrier</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-22-1.jpg" alt="Flowchart detailing the pathogenesis of bacterial meningitis from nasopharyngeal colonization to neuronal injury." class="content-image">
                            <figcaption>Pathogenesis and pathophysiology of bacterial meningitis</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: pathogenesis -->

                <!-- START: clinical-features -->
                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Symptoms and Signs of Bacterial Meningitis</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Rapid Onset (25%) hospitalized < 24h</li>
                            <li>Respiratory Symptoms days - weeks</li>
                            <li>Headache 90%</li>
                            <li>Fever >90%</li>
                            <li>Altered consciousness 80%</li>
                            <li>Vomiting - 30%</li>
                            <li>Seizures - 30%</li>
                            <li>Petechiae/purpura 50%</li>
                            <li>Meningismus 85%</li>
                            <li>Focal neurosigns 25%</li>
                            <li>Ocular palsies - 10%</li>
                            <li>Hemiparesis</li>
                            <li>Myalgias 20%</li>
                            <li>Papilledema 1%</li>
                        </ul>
                        <h3 class="subsection-heading">Clinical signs of meningeal irritation</h3>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-26-1.jpg" alt="Illustration of the Kernig's sign test for meningeal irritation." class="content-image">
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-26-2.jpg" alt="Illustration of the Brudzinski's sign test for meningeal irritation." class="content-image">
                        </figure>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-26-3.jpg" alt="Illustrations showing nuchal rigidity in an adult and a child." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: clinical-features -->

                <!-- START: diagnosis-and-management -->
                <section id="diagnosis-and-management" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Diagnosis and Management</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-27-1.jpg" alt="Management algorithm for infants and children with suspected bacterial meningitis, from initial assessment to treatment." class="content-image">
                            <figcaption>Management algorithm for infants (>1 month) and children with suspected bacterial meningitis</figcaption>
                        </figure>
                        
                        <h3 class="subsection-heading">Lumbar Puncture (LP)</h3>
                        <p>LP is crucial for diagnosis. Contraindications include:</p>
                        <ul>
                            <li>Respiratory distress (positioning)</li>
                            <li>↑ ICP reported to increase risk of herniation</li>
                            <li>Cellulitis at area of tap</li>
                            <li>Bleeding disorder</li>
                        </ul>
                        <h3 class="subsection-heading">CSF Evaluation</h3>
                        <div class="table-container">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>Condition</th>
                                        <th>WBC</th>
                                        <th>Protein (mg/dL)</th>
                                        <th>Glucose (mg/dL)</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Normal</td>
                                        <td>&lt;7, lymphs mainly</td>
                                        <td>5-45</td>
                                        <td>>50</td>
                                    </tr>
                                    <tr>
                                        <td>Bacterial, acute</td>
                                        <td>100 - 60K PMN's</td>
                                        <td>100-500</td>
                                        <td>Low</td>
                                    </tr>
                                    <tr>
                                        <td>Bacterial, part rx'd</td>
                                        <td>1-10,000</td>
                                        <td>100+</td>
                                        <td>Low to normal</td>
                                    </tr>
                                    <tr>
                                        <td>TB</td>
                                        <td>10-500</td>
                                        <td>100-500</td>
                                        <td>&lt;50</td>
                                    </tr>
                                    <tr>
                                        <td>Fungal</td>
                                        <td>25-500</td>
                                        <td>25-500</td>
                                        <td>&lt;50</td>
                                    </tr>
                                    <tr>
                                        <td>Viral</td>
                                        <td>&lt;1000</td>
                                        <td>50-100</td>
                                        <td>Normal</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                        
                        <h3 class="subsection-heading">Who Needs an LP?</h3>
                        <p>At a minimum, LP should be performed on those with a history of fever and one of:</p>
                        <ul>
                            <li>Bulging fontanelle</li>
                            <li>Stiff neck</li>
                            <li>Fits if age &lt;6 months or >6 years</li>
                            <li>Partial or focal fits</li>
                            <li>Reduced consciousness</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-41-1.jpg" alt="Child with a bulging fontanelle, a sign of increased intracranial pressure." class="content-image">
                        </figure>
                        
                        <h3 class="subsection-heading">Value of LP Findings</h3>
                        <p>75% of acute bacterial meningitis cases can be detected by examining for CSF cloudiness or turbidity at the bedside. Cloudiness usually appears at CSF WBC counts > 200 x 10⁶ Wbc per L. CSF should be crystal clear.</p>
                        
                        <h3 class="subsection-heading">Microscopy - Gram Stain</h3>
                        <ul>
                            <li>Absence of organisms on Gram stain does not exclude the diagnosis.</li>
                            <li>Gram-positive diplococci suggest S. pneumoniae.</li>
                            <li>Gram-negative diplococci suggest N. meningitidis.</li>
                            <li>Small pleomorphic Gram-negative coccobacilli suggest Hib.</li>
                            <li>Gram-positive cocci or coccobacilli suggest group B streptococcus.</li>
                            <li>Gram-positive rods and coccobacilli suggest L. monocytogenes.</li>
                        </ul>
                        <aside class="callout note" role="note">
                            <h4 class="callout-title"><span class="callout-icon"> </span> Note on Prior Antibiotics</h4>
                            <p>Prior antibiotic use reduces the sensitivity of CSF gram stain by 20% and CSF culture by 30%. However, it takes 2-3 days of therapy to change the WBC cell count of CSF in true bacterial meningitis. Prior treatment is no excuse for not doing an LP!</p>
                        </aside>
                    </div>
                </section>
                <!-- END: diagnosis-and-management -->

                <!-- START: treatment -->
                <section id="treatment" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <p>Empiric regimen for infants and children older than 1 month with bacterial meningitis include coverage for antibiotic-resistant S. pneumoniae, N. meningitidis, and Hib.</p>
                        <ul>
                            <li>Cefotaxime (300 mg/kg/d [IV], maximum dose 12 g/day, in 3 or 4 divided doses) or</li>
                            <li>Ceftriaxone (100 mg/kg/d IV, maximum dose 4 g/day in 1 or 2 divided doses) plus</li>
                            <li>Vancomycin (60 mg/kg per day IV, maximum dose 2 g/day, in 4 divided doses)</li>
                        </ul>
                        <h3 class="subsection-heading">Duration of Therapy</h3>
                        <ul>
                            <li>S. pneumoniae - 10 to 14 days</li>
                            <li>N. meningitidis - 5 to 7 days</li>
                            <li>Hib - 7 to 10 days</li>
                            <li>L. monocytogenes - 14 to 21 days</li>
                            <li>Gram-negative bacilli - 3 weeks or a minimum of 2 weeks beyond the first sterile culture, whichever is longer</li>
                        </ul>
                        <h3 class="subsection-heading">Dexamethasone Use</h3>
                        <ul>
                            <li>Consider if H. flu & S. pneumo meningitis & > 6 wks old (0.6 mg/kg/day ÷ Q 6 h x 2 d).</li>
                            <li>↓ local synthesis of TNF-α, IL-1, PAF & prostaglandins resulting in ↓ BBB permeability, ↓ meningeal irritation.</li>
                            <li>Debate if it ↓ incidence of hearing loss.</li>
                            <li>If used, needs to be given shortly before or at the time of antibiotic administration (within 1 hr).</li>
                            <li>May adversely affect the penetration of antibiotics into CSF.</li>
                        </ul>
                        <h3 class="subsection-heading">Meningococcemia Prophylaxis</h3>
                        <ul>
                            <li>Treat within 24 hours of exposure.</li>
                            <li>Vaccinate affected population, if outbreak.</li>
                            <li><strong>Rifampin:</strong> &lt;1 mo 5 mg/kg PO Q 12 x 2 days; >1 mo 10 mg/kg (max 600 mg) PO Q 12 x 2 days.</li>
                            <li><strong>Ceftriaxone:</strong> ≤12 y 125 mg IM x 1 dose; >12 y 250 mg IM x 1 dose.</li>
                            <li><strong>Ciprofloxacin:</strong> ≥18 y 500 mg PO x 1 dose.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: treatment -->

                <!-- START: tb-viral-meningitis -->
                <section id="tb-viral-meningitis" class="content-section" aria-labelledby="section-heading-8">
                    <h2 id="section-heading-8" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Tuberculous and Viral Meningitis</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Tuberculous Meningitis (TBM)</h3>
                        <p>A complication of childhood TB, common cause of prolonged morbidity, handicap, and death, especially in children below 5 years.</p>
                        <ul>
                            <li><strong>First Phase (Prodromal):</strong> Vague symptoms, child is dull, irritable, restless, or drowsy. Anorexia, vomiting, low-grade fever, personality change.</li>
                            <li><strong>Second Phase (Meningitic):</strong> Confusion, drowsy, neck stiffness, protracted headache, vomiting, lethargy, convulsions, cranial nerve palsies.</li>
                            <li><strong>Terminal Phase (Paralytic):</strong> Stupor and coma, opisthotonus, multiple focal paresis, high-grade fever.</li>
                        </ul>
                        <p><strong>Diagnosis:</strong> CSF shows profoundly low glucose and high protein. Steroids + anti-TB drugs are the treatment.</p>

                        <h3 class="subsection-heading">Viral Meningitis</h3>
                        <p>Comprises most aseptic meningitic syndromes. Agents include Enterovirus, Herpesvirus, Paramyxovirus, etc.</p>
                        <p><strong>Treatment:</strong> Supportive care, analgesia, fever control. No antibiotics needed. No isolation required (Standard precautions).</p>
                        <p><strong>Outcomes:</strong> Adverse outcomes are rare. Infants <1 year have a higher incidence of speech & language delay. For Herpes simplex 1 encephalitis, treat with IV acyclovir.</p>
                    </div>
                </section>
                <!-- END: tb-viral-meningitis -->

                <!-- START: complications -->
                <section id="complications" class="content-section" aria-labelledby="section-heading-9">
                    <h2 id="section-heading-9" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Complications</span>
                    </h2>
                    <div class="content-card">
                        <p>Acute complications of meningitis include:</p>
                        <figure>
                            <img src="../assets/images/2025_09_04_ec104c85896449bfde85g-72-1.jpg" alt="CT scan showing hydrocephalus as a complication of meningitis." class="content-image">
                        </figure>
                        <ul>
                            <li>Hydrocephalus</li>
                            <li>Subdural effusion or empyema (~30%)</li>
                            <li>Stroke</li>
                            <li>Abscess</li>
                            <li>Dural sinus thrombophlebitis</li>
                        </ul>
                    </div>
                </section>
                <!-- END: complications -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="neurology-febrile-seizures.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 84.6%;"></div>
                        </div>
                       <span class="progress-text">Lecture 11 of 13</span>
                    </div>
                    <a href="neurology-other-conditions.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>